Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Intercell Reaches Commercial Stage In US: Japanese Encephalitis Vaccine Gets FDA Okay

This article was originally published in The Pink Sheet Daily

Executive Summary

First vaccine approval for Intercell in US brings a new player fully into the vaccine business; Austrian company has key partnerships pending with Merck, Novartis and Sanofi.

You may also be interested in...



Intercell's Pipeline Setbacks Force Strategic Rethink, Highlight Downside of Option-Based Deals

Two high-profile pipeline setbacks over the past six months have prompted a wholesale strategic rethink at Austria's Intercell AG, one of the few remaining publicly quoted vaccine companies in Europe.

Intercell's Pipeline Setbacks Force Strategic Rethink, Highlight Downside of Option-Based Deals

Two high-profile pipeline setbacks over the past six months have prompted a wholesale strategic rethink at Austria's Intercell AG, one of the few remaining publicly quoted vaccine companies in Europe.

Growing Up: Vaccine Market Increasingly Targets Adults

This past spring, the executive team at 1Intercell AG received the proverbial shot in the arm. After a decade of research and testing, their Ixiaro vaccine for combating Japanese encephalitis was approved by the FDA and then recommended by the Advisory Committee on Immunization Practices

Related Content

Topics

UsernamePublicRestriction

Register

ID1131516

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel